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1. Introduction 
Polymyositis and dermatomyositis, the most important disease subsets in idiopathic 
inflammatory myopathies (IIMs), are heterogeneous conditions classically defined by a wide 
clinical spectrum including proximal skeletal muscle weakness, skin lesions and systemic 
organ involvement, particularly interstitial lung disease, in conjunction with biochemical 
and histopathological background of varying degrees of muscle inflammation 
(Gunawardena et al., 2008; Gunawardena et al., 2009;  Mimori et al., 2007).  
Although the exact etiology is still controversial, there is increasing evidence of aberrant 
autoimmunity in both entities, closely linked to different patterns of myositis-specific 
(MSAs) and myositis-associated autoantibodies (MAAs) (Gunawardena et al., 2009; Mimori 
et al., 2007).  
Currently recognized as disease biomarkers, myositis-specific autoantibodies have been 
identified as key players in IIMs, promoting several pathogenic pathways as they target 
cytoplasmic and nuclear proteins involved in basic cellular processes (protein synthesis, 
nuclear transcription and translocation), but also being directly connected to phenotype 
disease profiles (Betteridge et al., 2007; Gunawardena et al., 2008; Gunawardena et al., 2009; 
Mimori et al., 2007).  
While several subsets of myositis-specific autoantibodies targeting both classic (aminoacyl-
tRNA synthetases, ARSs, signal recognition particle, SRP, and Mi-2) and newly identified (MJ, 
PMS1, CADM140, p-155/p-140, SAE) autoantigens have been fully described in polymyositis 
and dermatomyositis (Gunawardena et al., 2009; Hengstman et al., 2004; Suber et al., 2008), the 
most widespread group of myositis-specific autoantibodies is represented by anti-aminoacyl-
tRNA synthetase autoantibodies (Gunawardena et al., 2008; Gunawardena et al., 2009).  
Advancing knowledge in the field of synthetases, either antigenic or non-antigenic subtypes, 
has been reflected in critical association between genotype, serotype, clinical phenotype and 
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therapeutic potential in IIMs (Gunawardena et al., 2008; Gunawardena et al., 2009; 
Mammen, 2010).        
In this review we emphasize current concepts regarding the pathogenic role, clinical 
significance and potential therapeutic implications of aminoacyl-tRNA synthetases and their 
specific autoantibodies in idiopathic inflammatory myopathies. 
2. Aminoacyl-tRNA synthetases and their specific autoantibodies 
New findings on classical and novel aminoacyl-tRNA synthetases and their corresponding 
autoantibodies are analyzed in this section. 
2.1 Aminoacyl-tRNA synthetases (ARSs) 
The aminoacyl-transfer (t) RNA synthetases (ARSs), one of the major targets for 
autoimmune response in IIMs, represent a distinct group of cytoplasmic enzymes that 
catalyze the binding of specific aminoacids to their cognate transfer RNAs (tRNAs) in an 
energy-dependent manner (Hirakata, 2005; Mimori et al., 2007; Wikipedia, 2011).   
The ARSs are functionally-related, ubiquitously expressed enzymes involved in protein 
synthesis (Betteridge et al., 2007; Gunawardena et al., 2009, Shirakawa et al. 2005). A unique, 
immunologically and enzymatically distinct aminoacyl-tRNA is characteristically assigned 
to each of the currently known 20 aminoacids (Hirakata, 2005; Mammen, 2010), transferring 
the appropriate aminoacid to an elongated polypeptide chain (Mammen, 2010).     
Eight autoantigenic synthetases have been identified so far. Six out of eight are recognized 
as classical ARSs and are represented by Jo-1 (histidyl-tRNA synthetase: HisRS), PL-7 
(threonyl-tRNA synthetase: ThrRS), PL-12 (alanyl-tRNA synthetase: AlaRS), EJ (glycyl-
tRNA synthetase: GlyRS), OJ (isoleucyl-tRNA synthetase: IsoRS) and KS (asparaginyl-tRNA 
synthetase: AsnRS) (Hirakata, 2005; 7, Mimori et al, 2007; Shirakawa et al., 2005).  
Additionally, two novel subsets of synthetases have been recently described as being 
autoantigenic, including Zo (phenylalanyl-tRNA synthetase: PheRS) and YRS or Ha (┙ and 
┚ chains of tyrosyl-tRNA synthetase: TyrRS), respectively (Betteridge et al., 2007; Mimori et 
al., 2007).  
Specific autoantibodies targeting the aforementioned synthetases have been commonly 
encountered in connective tissue disorders, particularly in 25 to 35% of patients with 
polymyositis and dermatomyositis (Hirakata, 2005; Mimori et al., 2007; Park et al., 2008).     
Based on distinct enzymatic properties, sequence motifs, molecular structure and the site of 
initial aminoacylation, ARSs can be divided in two main classes (Betteridge et al., 2007; 
Hirakata, 2005; Woese et al., 2000; Wikipedia, 2011). Class I ARSs comprises a multi-
enzymatic complex with anti-synthetasic specificity for nine different amino acids, whereas 
Class II ARSs are typically found free and uncomplexed in the cellular cytoplasm. Since OJ 
or isoleucyl-tRNA synthase is part of such multi-enzyme complex, specific anti-OJ 
antibodies can react also against multiple synthetases; however, the specific anti-OJ pattern 
is not shaped (Betteridge et al., 2007; Hirakata, 2005; Woese et al., 2000). On the other hand, 
five classical synthetases, both Jo-1 and non-Jo1 subtypes (PL-7, PL-12, EJ and KS), are 
further classified as Class II members.       
It is widely accepted that not all synthetases are autoantigenic in patients diagnosed with 
either polymyositis or dermatomyositis (Hirakata, 2005). Besides, ARSs are not randomly 
targeted as several autoantibodies like anti-Jo-1 are more prevalent than the others 
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(Hirakata, 2005; Mimori et al., 2007), perhaps directly related to their accessibility and 
expression on the cell surface (Hirakata, 2005).   
2.2 Anti-aminoacyl-tRNA synthetases auto-antibodies 
Overall, eight different autoantibodies reacting with autoantigenic ARSs have been 
recognized, specifically described as anti-Jo-1 and anti-non Jo-1 antibodies. The anti-non-Jo-
1 subtypes refer to us as anti-PL-7, anti-PL-12, anti-OJ, anti-EJ, anti-KS, anti-Zo and anti-YRS 
or anti-Ha antibodies (Hirakata, 2005; Mimori et al., 2007; Solomon et al., 2011). 
Several characteristics of these anti-ARSs autoantibodies have been emphasized (Betteridge 
et al., 2009; Hirakata, 2005; Solomon et al., 2011; Targoff, 2008):  
 they focus on functionally related protein enzymes (synthetases) implicated in normal 
vital cellular cycle, specifically targeting muscle and lung tissue; 
 they are highly selective, each autoantibody being directed to only one synthetase;  
 they are mutually exclusive in a given patient, with a few exception only a single anti-
synthetase being typically found; 
 they are generally associated with particular phenotypes, a characteristic clinical 
syndrome being known as “anti-synthetase syndrome”, although distinct profiles are 
defined for each autoantibody; and  
 they are associated with particular genotypes.  
Even thought to represent only disease biomarkers, it seems that anti-synthetase 
autoantibodies are active players in the immunopathogenesis of polymyositis and 
dermatomyositis. However, if the anti-ARSs autoantibodies are simply epiphenomena or 
directly linked to disease mechanisms remain an open question. Several fascinating 
paradigms have been effectively anticipated to explain why and how certain intracellular 
proteins, widely originating in all cellular types, are selectively and specifically targeted in 
IIMs (Betteridge et al., 2009).  
Anti-ARS autoantibodies are associated with anti-synthetase syndrome (ASS), classically 
defined by several characteristic clinical features including myositis, interstitial lung disease 
(ILD), arthritis, fever, Raynaud’s phenomenon and “mechanic’s hands”, in addition to other 
typical skin lesions such as Gottron’s papules and heliotrope rash (Betteridge et al., 2007; 
Betteridge et al., 2009; Gunawardena et al., 2009; Hirakata, 2005). Moreover, distinct 
associations between certain anti-synthetases profile and corresponding clinical pattern 
have actually been up-dated.  
Specific anti-synthetase autoantibodies detected in polymyositis and dermatomyositis and 
their target are listed in Table 1.  
 
Anti-synthetase antibody 
Target autoantigen (aminoacyl-tRNA 
synthetase) 
Frequency in IIMs (%) 
Anti-Jo-1 Histidyl-tRNA synthetase 15 - 20 
Anti-non-Jo-1 
 anti-PL-7 
 anti-PL-12 
 anti-OJ 
 anti-EJ 
 anti-KS 
 anti-Zo 
 
 anti-YRS (anti-Ha) 
 
Threonyl- tRNA synthetase 
Alanyl- tRNA synthetase 
Glycyl - tRNA synthetase 
Isoleucyl - tRNA synthetase 
Asparaginyl- tRNA synthetase 
Phenylalanyl-tRNA synthetase 
┙ and ┚ chains 
tyrosyl- tRNA synthetase 
 
5 – 10 
< 5 
5 – 10 
< 5 
< 5 
< 1 
 
< 1 
Table 1. Anti-synthetase autoantibidies in IIMs: targets and frequencies. 
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3. Immunopathogenic significance of aminoacyl-tRNAs in myositis 
Recent evidences have highlighted the role of autoantigenic aminoacyl-tRNA synthetases 
and their specific autoantibodies in the initiation and progression of myositis. Although 
the exact sequence of events still remains under debate, several pathways are actually 
proposed including (i) enhanced expression of aminoacyl synthetases in different target 
tissues, particularly in muscle and lung, (ii) potential role of proteolytic cleavage 
fragments of aminoacyl-tRNA synthetases generated during inflammation and apoptosis 
in lesional tissues (muscle and lung), and (iii) autoantigen signaling through chemokine 
receptors with subsequent amplification of the inflammatory and autoimmune response 
(Hirakata, 2005).  
A detailed insight into the ethiopathogenic mechanisms of myostis, along with genetic 
susceptibility and adjuvant environmental triggers will be further discussed in this 
section. 
3.1 Enhanced aminoacyl-tRNA synthetase expression in lesional tissues 
Increased synthesis of specific antibodies subsets targeting restricted series of autoantiogens 
in myositis has been extensively debated. Recent findings have suggested that the 
modification of biochemical structure of different proteins with consecutive augmented 
antigenicity is essential in guiding their selection as targets (Howard et al, 2003). 
Moreover, posttranslational modification of proteins as well as proteolytic cleavage of 
autoantigens by the direct intervention of either caspases or granzyme B leading to 
proteolytic fragments with enhanced autoantigenicity might contribute to the initiation and 
propagation of autoimmunity (Casciola-Rosen et al., 1999; Darrah & Rosen, 2010; 
Gunawardena et al., 2009; Howard et al, 2003). 
It can be hypothesized that up-regulation of certain autoantigens in specific target tissues as 
muscle and lung play a key role in myositis induction, as the main source of antigens 
(Betteridge et al., 2009; Mimori et al., 2007). Additionally, based on augmented expression of 
autoantigens in the lung and skeletal muscle, it has been emphasized the potential 
significance of distinct microenvironments in determining the specific autoimmune 
response in IIMs with or without lung involvement (Betteridge et al., 2009; Levine et al., 
2007).         
Current reports have indicated increased expression of autoantigens, both myositis-specific 
and myositis- associated subgroups, in muscle fibers from patients with IIMs, particularly in 
damaged and regenerating cells (Casciola-Rosen et al., 2005). While most autoantigens are 
frequently expressed in a tissue-restricted manner, aminoacyl-tRNA synthetases are 
targeted only in autoimmune myositis and, therefore, markedly expressed in injured muscle 
(Betteridge et al., 2009; Gunawardena et al., 2008; Gunawardena et al., 2009; Mimori et al., 
2007).  
Enhanced ARSs expression was mainly described for histidyl-tRNAsynthetase (Jo-1), 
supporting the hypothesis that the presence of challenger autoantigens during reparative 
myogenesis promotes aberrant autoimmune response (Betteridge et al., 2009; Gunawardena 
et al., 2008; Gunawardena et al., 2009; Mimori et al., 2007).  
Concomitant up-regulation of major histocompatibility complex (MHC) class I has been 
already reported in the affected muscle cells, while either very low or normal levels of 
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myositis-specific and associated antigens are detected in normal skeletal muscle (Betteridge 
et al., 2009; Mimori et al., 2007). 
3.2 Proteolytic granzyme B cleavage of aminoacyl-tRNA synthetase and intervention 
in interstitial lung disease    
It is well known that the autoantigenic fragments resulted by the specific intervention of 
granzyme B serine protease on aminoacyl-tRNA synthetase substrates are actually essential 
for myositis induction and development during IIMs (Betteridge et al., 2009; Casciola-Rosen 
et al., 1999; Darrah & Rosen, 2010; Levine et al., 2003; Levine et al, 2007).  
Besides, it has been demonstrated that the susceptibility of these antigenic synthetases to 
cleavage by granzyme B is highly predictive of autoantigen status in myositis (Casciola-
Rosen et al., 1999). Not only histidyl-tRNA, but also two other synthetases, isoleucyl-tRNA 
and alanyl-tRNA synthetases, are cleaved by granzyme B leading to the release of 
autoantigenic epitopes (Betteridge et al., 2009; Casciola-Rosen et al., 1999; Levine et al, 2007).  
Current reports support also the hypothesis that the expression of different autoantigens is 
not uniformly defined across all tissues and may be modified in disease-specific milieu such 
as inflamed muscle and lung in patients with polymyositis and dermatomyositis (Levine et 
al, 2007). 
Interestingly, two isoforms of autoantigenic His-RS with different susceptibility to cleavage 
by proteolytic enzymes, and, subsequent, distinct immunogenic properties have been 
recently identified (Katsumata et al, 2007; Levine et al, 2007; Mammen, 2010); the granzyme 
B cleavage site has been detected only in the novel described conformation. Furthermore, 
although the overall expression of His-RS/Jo-1 in specific target tissues (muscle, lung) is the 
same, the novel isoform is highly expressed in the epithelium of the lung and may be one 
factor that generates auto-immunity at this level (Labirua & Lundberg, 2010; Lundberg & 
Grundtman, 2008; Mammen, 2010). Cleavage with granzyme B result in the generation of 
cryptic Jo-1 fragments with increased antigenicity and subsequent immune response 
(Shirakawa et al., 2005). 
As a consequence, the aforementioned paradigm that distinct microenvironments may 
influence disease expression was highlighted with the identification of high expression of 
this new Jo-1 conformation resulted by proteolytic cleavage in the lung (Casciola-Rosen et 
al., 1999; Darrah & Rosen, 2010; Labirua & Lundberg, 2010; Levine et al, 2007; Lundberg & 
Grundtman, 2008). 
Furthermore, it has been proposed that the initiating target tissue for the autoimmune 
response in the anti-Jo-1 syndrome is the lung with secondary attack of muscle 
(Gunawerdana et al., 2009). In addition, a modification of aminoacyl-tRNA synthetases in 
the lung could lead to production of autoantibodies (antisynthetase antibodies), a second, 
event being required for the immune reaction to direct against muscle or other organs 
(Gunawardena et al., 2008). How the anti-Jo-1 immune response originating in the lung 
might be redirected to skeletal muscle cells still remain an open question (Mammen, 2010).  
3.3 Pro-inflammatory and chemo-attractant properties of autoantigenic aminoacyl-
tRNA synthetases 
Aminoacyl-tRNA synthetases and their proteolytic fragments as a result of inflammatory 
and apoptotic processes seem to hold chemo-attractant properties, inducing specific 
autoimmune response in IIMs (Hirakata, 2005). 
Recent works have demonstrated that enhanced expression of autoantigenic ARSs as well as 
specific cytokines and chemokines pattern are broadly involved in the initial recruitment 
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and amplification of muscle-specific inflammatory response, since ARSs exhibit significant 
pro-inflammatory and specifically chemo-attractant potential (Betteridge et al. 2007; 
Betteridge et al. 2009; Howard, 2006). 
Furthermore, the chemo-attractant properties of ARSs might contribute to their selection as 
targets in myositis, not only in muscle but also in lung tissue (Howard et al., 2002). This may 
therefore suggest a role for tRNA synthetases in the pathogenesis of myositis and interstitial 
lung disease itself (Betteridge et al., 2007, Betteridge et al., 2009; Howard, 2006). 
Advanced studies on the ability of aminoacyl-tRNA synthetases to induce leukocyte 
migration have revealed distinct profiles according to the ARSs subset (Howard et al, 2003).  
Therefore, histidyl-, asparaginyl- and tyrosyl-tRNA syntetases feature chemo-attractant 
properties and promote CD4+ and CD8+ lymphocytes, interleukin (IL)-2-activated 
monocytes and immature dendritic cells migration through the intervention of CCR5 and 
CCR3 receptors. Indeed, while His-RS specifically functions as a nonchemokine chemo-
attractant for cells expressing CCR5 (Howard et al, 2003; Mammen, 2010), Asn-RS is known 
to generate the migration of CCR3-bearing cells (Howard et al, 2003; Kron et al., 2005).  
Additionally, both aminoacyl-tRNA synthetases hold the potential to attract immature 
dendritic cells, participating in the initiation of an adaptive immune response with 
subsequent autoantibody synthesis and perpetuation of autoimmune-mediated muscle 
damage (Howard et al, 2003; Mammen, 2010). In fact, most autoantigens are chemotactic for 
immature dendritic cells, enhancing their ability to connect the innate and the adaptive 
immune systems (Howard, 2006).  
Further, both His-tRNA and Asn-tRNA synthetases induce the activation and subsequent 
migration of newly cells expressing their chemokine receptor. In turn, these leukocytes 
perpetuate the vicious circle by releasing a wide range of other chemokines and activating 
other immune cells leading to magnification of inflammatory process during IIMs (Howard, 
2006).      
Conversely, neutrophils, mature dendritic cells and unstimulated monocytes are not 
influenced by the presence of ARSs (Gunawardena et al., 2009; Howard et al, 2006).  
On the other hand, non-antigenic aspartyl- and lysyl-tRNA synthetases do not exert 
proinflammatory chemo-attractant properties, as such ARSs do not activate chemokine 
receptors (Gunawardena et al., 2009; Howard et al, 2003; Howard et al, 2006).  
Finally, there is now increase evidence that the local abundance of pro-inflammatory 
autoantigenic ARSs (perhaps liberated from damaged and regenerating muscle cells) may 
not only provide the reason for autoantibody synthesis, but also may expand the 
inflammatory process and immune-mediated muscle damage (Howard et al, 2003; Kron et 
al., 2005; Mammen, 2010).  
3.4 Anti-Jo-1 autoantibodies   
It was already emphasized that not only antigenic synthetases, but also their specific 
autoantibodies might contribute to IIMs pathogenesis (Gunawerdana et al., 2008). This 
model has been validated for anti-Jo-1 autoantibodies, particularly for the association 
between anti-SSA/Ro-52 (and not anti-SSA/Ro-62) and anti-Jo-1, recognized as 
endogeneous type 1 IFN-inducer (Betteridge et al., 2009; Gunawerdana et al., 2008; Labirua 
& Lundberg, 2010).  
The co-existence of anti-SSA/Ro with anti-Jo-1 has been reported in up to 60% of anti-Jo-1 
positivity cases and seems to be essentially involved in promoting IFN synthesis (Betteridge 
et al., 2009; Eloranta et al., 2007; Gunawerdana et al., 2008). Moreover, up-regulation of type-
1 IFN-induced genes has been depicted in IIMs (Betteridge et al., 2009; Walsh et al., 2007). 
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On the other hand, it is well known that IFN type 1 plays a role in the pathogenesis of 
myositis, being fundamentally related to disease propagation (Betteridge et al., 2009).  
3.5 Cancer, myositis and anti-aminoacyl-tRNA synthetases 
Since the relationship between myositis, particularly adult dermatomyositis, and cancers is 
well establish, there is increasing evidence for the role of the members of aminoacyl-tRNA 
synthetases family as autoantigenic targets in malignancies (Betteridge et al., 2009; Chinoy et 
al., 2007; Mimori et al., 2007); while most studies concentrate on the contribution of hystidil-
tRNA, tyrosyl-tRNA, isoleucyl-tRNA, phenylalanyl-tRNA and glycil-tRNA synthetases in 
malignancy-associated myositis, recent data focus on preferential expression of the alpha-
chain of phenylalanyl-tRNA synthetase not only in interstiatial lung disease and solid lung 
tumours, but also in acute myeloid leukaemia (Betteridge et al., 2009). In addition, Jo-1 is 
highly expressed in lung and breast adenocarcinoma (Betteridge et al., 2009; Mimori et al., 
2007). 
Furthermore, it has been suggested that there may be a relative increased expression of the 
proteolytic enzymes such as granzyme B in carcinoma cells, with subsequent increase in 
autoimmune fragments and cryptic epitopes, and aberrant autoimmune response in skeletal 
muscle (Betteridge et al., 2009; Mimori et al., 2007). Additionally research is mandatory to 
support the cross-reactivity to tumor-related antigens in muscle (Betteridge et al., 2009; 
Mimori et al., 2007).          
3.6 Environmental factors 
It is widely accepted that myositis occurs in genetically susceptible recipients and that 
external antigens could trigger an aberrant immune response in target tissues such as lungs 
or skeletal muscle (Gunawardena et al., 2009; Mimori et al., 2007). Besides, the paradigm of 
myositis with or without interstitial lung disease has been extensively highlighted based on 
the link between immunogenetic profiles, autoimmune targets and clinical phenotype 
(Betteridge et al., 2009; Labirua & Lundberg, 2010; Targoff, 2008).  
Additional evidence is directed towards the key role of infection in the development of 
muscular damage, particularly the interaction between myogenic RNA viruses with tRNA-
like structures and ARSs, with consecutive abnormal autoimmunity face to cryptic epitopes 
(Betteridge et al., 2009; Gunawardena et al., 2009; Mimori et al., 2007).  
Molecular mimicry between myositic autoantigenic ARS substrates and viral proteins with 
increasing antigenicity represents an attractive hypothesis that may modulate the immune 
response and the development of autoimmune myositis (Mimori et al., 2007).   
Also, current data support the role of several geoclimatic variables and seasonal patterns in 
the development of specific serologic myositis subsets; thus, in patients with anti-ARS 
autoantibodies, particularly anti-Jo-1 positive cases, the onset of myositios seems to peak in 
spring (Gunawardena et al., 2009; Sarkar et al., 2005).  
4. Clinical significance of aminoacyl-tRNA synthetases and management of 
anti-synthetase syndrome  
Considerable progress focusing on the striking association between serotype and clinical 
phenotype has been made in myositis.  
Whereas highly selective, mutually exclusive and associated with particular genotypes with 
few exceptions, anti-synthetase autoantibodies are strongest associated with the anti-
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synthetase syndrome, a disease subset characterized by a broad clinical spectrum including 
varying degrees of (i) interstitial lung disease (ILD), (ii) myositis, (iii) non-erosive 
(poly)arthritis, (iv) fever, (v) Raynaud’s phenomenon and (vi) “mechanic’s hand” meaning 
hyperkeratosis with fissuring and hyperpigmentation along the radial and palmar aspects of 
the fingers (Betteridge et al., 2007; Hirakata, 2005; Mimori et al., 2007; Solomon et al., 2011).  
More detailed clinical features, investigations and specific management of patients with 
anti-ARS antibodies have been described in several recent reports (Betteridge et al., 2009; 
Hirakata, 2005; Koenig, 2007; Solomon et al., 2011).  
Current findings on autoantibodies in anti-synthetase syndrome have already provided 
important information about clinical phenotypes, course and prognosis related to anti-ARSs 
status (Lundberg & Grundtman, 2008; Labirua & Lundberg, 2010).  
Therefore, data about antibody profile may predict the clinical course of interstitial lung 
disease in patients with polymyositis and dermatomyositis (Yoshifuji et al., 2006; Labirua & 
Lundberg, 2010; Mimori et al., 2007); anti-ARSs positive patients had significantly higher 
frequency of lung involvement than negative cases (70-95% versus 40%) (Mimori et al., 
2007). 70% or more of the anti-ARSs positive cases have ILD and only 40-50% muscle 
pathology, milder than in anti-ARSs negative patients and even subclinical (Labirua & 
Lundberg, 2010; Lundberg & Grundtman, 2008). Moreover, in the majority of anti-ARSs 
positive disease, ILD was diagnosed at the same time or before the onset of myositis 
(Mimori et al., 2007). There is increasing evidence that ILD is commonly associated with 
anti-non-Jo-1 positivity, particularly with the presence of anti-PL-7 and anti-PL-12 
antibodies (Labirua & Lundberg, 2010; Targoff, 2008).    
Anti-ARSs positivity in patients with ILD and myositis showed more favorable clinical 
outcomes with better response to first-line corticosteroids, but developed significant higher 
recurrence rate versus anti-ARSs negative cases (Labirua & Lundberg, 2010; Mimori et al., 
2007). Conversely, it seems that the 2-year prognosis of pulmonary function was not 
different based on anti-ARSs status (Mimori et al., 2007).  
The detection of anti-ARS antibodies is an important predictor for late-onset skeletal muscle 
pathology in patients with ILD and the clinical course of ILD in myositis (Mimori et al., 
2007).     
Although patients with anti-synthetase syndrome typically develop common clinical signs 
and symptoms, there is increasing evidence that autoantibody profile is associated with 
particular clinical subgroups (Labirua & Lundberg, 2010; Mimori et al., 2007; Sato et al., 
2007; Targoff, 2008). However, the exact mechanisms responsible for this clinical diversity 
are still unknown.  
Detailed insights into clinical picture of distinct anti-synthetase syndrome are further 
presented and summarized in table 2.  
4.1 Anti-Jo-1 positive anti-synthetase syndrome 
Anti-Jo-1 (anti-HisRS) autoantibody. Anti-Jo-1 was the first discovered and characterized 
autoantibody from the eight currently described anti-synthetases and, in the mean time, the 
most common anti-ARSs antibody ( Betteridge et al., 2009; Solomon et al., 2011). Most anti-
Jo-1 positive patients have been diagnosed with polymyositis (20-30%), while only 5 to 10% 
of cases have dermatomyositis; overall, nearly 75% of all anti-ARS cases present with anti-
Jo-1 positivity (Labirua & Lundberg, 2010; Mileti et al., 2009) and anti-Jo-1 is found in 15 to 
20 % of all myositis patients (Mimori et al., 2007).  
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Anti-ARSs antibody 
Anti-synthetase 
syndrome cinical 
spectrum 
Clinical subsets 
Anti-Jo-1 Myositis 
Arthritis (75%); Raynaud (50%); 
mechanic’s hand (20%) 
Anti-PL-7 
Lung involvement 
interstitial pneumonia 
Interstitial lung disease (up to 100%); 
infrequent myositis (40%); 
polymyositis/ scleroderma overlap 
syndrome 
Anti-PL-12 
Skin involvement 
mechanic’s hands 
Gottron’s papules 
Interstitial lung disease (70-100%); 
pulmonary hypertension; myositis (0-
50% to 60-100%); amyopatic ASS 
(60%); Raynaud (40-100%); rare 
mechanic’s hand 
Anti-OJ 
Joint involvement 
non erosive 
(poly)arthritis 
Interstitial lung disease (95%); rare 
myositis or Raynaudphenomenon 
Anti-KS Fever Interstitial lung disease 
Anti-Zo Raynaud phenomenon 
Severe non-specific interstitial 
pneumonia, proximal myopathy, 
Raynaud and arthralgia 
Anti-YRS/Ha  
Skin rash, muscle weakness, 
interstitial lung disease and arthritis 
Table 2. Anti-aminoacyl-tRNA synthetase antibodies, anti-synthetase syndrome and 
particular clinical phenotipes. 
Certain genotypic, immunological, histopathological and clinical characteristics have been 
demonstrated among anti-Jo-1 positive patients, with particular relevance for their 
prognosis (Solomon et al., 2011; Zampieri et al., 2005).  
Recent studies on the association between anti-Jo-1 levels and myositis activity have shown 
the presence of a direct correlation, even if modest, with creatine kinase levels, myositis, 
articular and pulmonary disease status (Gunawardena et al., 2009; Stone et al., 2007). 
Furthermore, it seems that anti-Jo-1 positivity is the strongest predictor of ILD in 
polymyositis and dermatomyositis, over 70% of those patients featuring lung disease 
(Solomon et al., 2011). The true incidence of myositis in anti-Jo-1 anti-synthetase syndrome 
is difficult to evaluate, since either biochemical or clinical significant disease might be 
reported (Mileti et al., 2009; Solomon et al., 2011).     
A particular subset of anti-Jo-1 positive anti-synthetase syndrome has been described in 
patients with the association between anti-Jo-1 and anti-SSA/Ro-52; the clinical phenotype 
of such patients showed severe extensive lung pathology (interstiytial lung fibrosis), with 
higher activity and damage scores and adverse outcomes, even with aggressive 
immunosupresive therapy (Labirua & Lundberg, 2010)            
4.2 Anti-Jo-1 negative anti-synthetase syndromes 
Anti-PL-7 (anti-ThrRS) autoantibody. Clinical characteristics of anti-PL-7 positive anti-
synthetase syndrome have also been described. Compared to anti-Jo-1 positive ASS, patients 
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with anti-PL-7 positivity appear to have a higher incidence of pulmonary disease (up to 
100%) associated with a lower incidence of myositis (about 40%) (Labirua & Lundberg, 2010;  
Mimori et al., 2007;  Solomon et al., 2011). Lower serum muscle enzymes (creatinine kinase) 
and milder muscle pathology in Japanese cases, as well as polymyositis–scleroderma 
overlap syndrome with idiopathic interstitial pneumonitis, arthritis and sclerodactyly have 
been also reported in patients with anti-PL7 autoantibodies (Gunawardena et al., 2009; 
Mimori et al., 2007; Sato et al., 2007).   
Anti-PL-12 (anti-AlaRS) autoantibodys. It should be noted that the clinical spectrum of 
anti-PL-12 positive anti-synthetase syndrome varies from interstitial lung disease (70-100%) 
to myositis (earlier reports 60-100%, but recent ones with a smaller proportion of 0-50%) and 
Raynaud’s phenomenon (40-100%), but rare mechanic’s hand (Hirakata, 2005; Kalluri et al., 
2009; Labirua & Lundberg, 2010; Solomon et al., 2011; Tzioufas, 2001).  
Moreover, compared to anti-Jo-1 positive anti-synthetase syndrome, patients with anti-PL-
12 positivity account for higher incidence of lung and lower incidence of muscle pathology 
(Gunawardena et al., 2009; Hervier et al., 2010). In the mean time, anti-PL-12 antibodies 
were also revealed in up to 60% of cases presenting with amyopatic anti-synthetase 
syndrome and non-specific interstitial pneumonia (Gunawardena et al., 2009; Hirakata, 
2005;  Solomon et al., 2011).  
Reports of higher pulmonary hypertension with hystologically proven intimal proliferation 
in the pulmonary arteries, and esophageal involvement have been registered in a limited 
number of cases (Hirakata, 2005; Labirua & Lundberg, 2010; Solomon et al., 2011). Finally, 
prognosis seems to depend on severity of ILD and the response to immunosuppressive 
therapy is variable (Solomon et al., 2011).  
Anti-OJ (anti-IsoRS) autoantibody. Anti-OJ antibodies are found in up to 2% of 
polymyositis and dermatomyositis patients (Sato et al., 2007; Solomon et al., 2011). It is 
classically accepted the association between interstitial pneumonia and non-Jo-1 anti-ARS 
antibodies including anti-OJ, the reported prevalence being as high as 95%; furthermore, it 
seems that patients with lung disease in the absence of clinically apparent myositis are 
closely related to anti-OJ subset (Betteridge et al., 2009, Gunawardena et al., 2009; Mimori et 
al., 2007).  
Additionally, one study conducted in Japanese patients has recently concluded that the 
presence of anti-OJ antibodies may distinguish a subtype of anti-ARS syndrome that is more 
closely associated with ILD than myositis or Raynaud’s phenomenon (Mimori et al., 2007; 
Sato et al., 2007). Moreover, anti-OJ was found to be useful for the diagnosis of patients with 
ILD with or without myositis (Sato et al., 2007).  
Anti-KS (anti-AsnRS) autoantibody. Clinical and immunogenetic characteristics have 
recently focused on interstitial pneumonia that may predominate in ASS with non-Jo-1 anti- 
ARS antibodies including anti-KS (Gunawardena et al., 2009; Mimori et al., 2007), but also 
on stronger association with ILD than myositis (Hirakata et al., 2007; Sato et al., 2007). 
Anti-Zo (anti-PheRS) autoantibody. The newly identified anti-Zo antibodies directed 
against autoantigenic alpha and beta chains of PheRS have been recently detected in only 
one patient with typical features of ASS, namely severe non-specific interstitial pneumonia, 
proximal myopathy, Raynaud’s phenomenon and arthralgia (Betteridge et al., 2009, Mimori 
et al., 2007; Solomon et al., 2011), by using proteomic analysis of immunopprecipitation and 
immunoblotting. 
Anti-YRS or anti-Ha (anti-TyrRS) autoantibody. Another novel antibody targeting TyrRS 
has been identified in one case of typical clinical pattern of ASS, particularly the association 
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between skin rash, muscle weakness, interstitial lung disease and arthritis (Hashish et al., 
2005; Mimori et al., 2007). 
4.3 Therapeutic consideration 
Latest findings have clearly demonstrated the association between aminoacyl-tRNA 
synthetases and their corresponding specific autoantibodies profiles in patients with IIMs 
with clinical and therapeutic implications. Moreover, the prevalence, course and severity of 
interstitial lung disease are significantly influenced by the autoantibody pattern. 
Accordingly, it seems that crucial decision on possible therapeutic options and subsequent 
disease outcomes and prognosis are fundamentally guided by the presence of different 
antibodies subsets (Baer, 2006; Labirua & Lundberg, 2010).  
Classically, high doses of steroids, as first-line therapy, in association with second-line 
immunosuppresors including azathioprine, cyclophosphamide, cyclosporine, mycophenolate 
mofetil or tacrolimus could be effective in such patients (Baer, 2006; Hervier et al., 2009; 
Labirua & Lundberg, 2010). Aggressive therapy such as intravenous immunoglobulins or 
newer biological are controversial, as there are no data to define firmly long-term disease 
outcomes in such conditions. Furthermore, advancing knowledge about the potential benefits 
of rituximab, an anti-CD20 monoclonal antibody, in life threatening antisynthetase syndrome 
provide conflicting data (Ball et al., 2010; Labirua & Lundberg, 2010; Sem et al., 2009; 
Vandenbroucke et al., 2009).  
An attractive therapeutic approach fundamentally based on antagonists of the targeted 
chemokine receptors has already been proposed, but not yet validated; the design of such 
intervention was suggested by the paradigm of chemokine receptor mediated cell migration 
triggered by autoantigens like aminoacyl-tRNA synthetases (Howard, 2006).                  
5. Conclusion 
There is now emerging evidence supporting the fundamental role of specific aminoacyl-
tRNA synthetases and their corresponding autoantibodies in the initiation, propagation and 
expression of myositis spectrum.  
Furthermore, detailed insights into the pathways of myostis emphasizes the critical 
contribution of up-regulated synthetase expression in target tissues, particularly in muscle 
and lung, proteolytic cleavage fragments generated during inflammation and apoptosis in 
specific microenvironments and autoantigen signaling through chemokine receptors with 
subsequent amplification of the inflammatory and autoimmune response.  
The paradigm of distinct anti-aminoacyl-tRNA synthetase autoantibody pattern shaping the 
clinical features and course of the generic anti-synthetase syndrome to specific phenotypes 
is actually wide accepted.    
Considerable progress focusing on the striking association between serotype and clinical 
phenotype may be the fundamental for further development of more specific therapeutic 
options. 
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